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Abstract
The	SLC3	and	SLC7	families	combine	to	generate	functional	transporters,	where	the	subunit
composition	is	a	disulphide-linked	combination	of	a	heavy	chain	(SLC3	family)	with	a	light	chain
(SLC7	family)	[1].
Contents
This	is	a	citation	summary	for	SLC3	and	SLC7	families	of	heteromeric	amino	acid	transporters
(HATs)	in	the	Guide	to	Pharmacology	database	(GtoPdb).	It	exists	purely	as	an	adjunct	to	the
database	to	facilitate	the	recognition	of	citations	to	and	from	the	database	by	citation	analyzers.
Readers	will	almost	certainly	want	to	visit	the	relevant	sections	of	the	database	which	are	given	here
under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.
GtoPdb	is	a	reference	work	which	is	most	usefully	represented	as	an	on-line	database.	As	in	any
publication	this	work	should	be	appropriately	cited,	and	the	papers	it	cites	should	also	be	recognized.
This	document	provides	a	citation	for	the	relevant	parts	of	the	database,	and	also	provides	a
reference	list	for	the	research	cited	by	those	parts.	For	further	details	see	[2].
Please	note	that	the	database	version	for	the	citations	given	in	GtoPdb	are	to	the	most	recent
preceding	version	in	which	the	family	or	its	subfamilies	and	targets	were	substantially	changed.	The
links	below	are	to	the	current	version.	If	you	need	to	consult	the	cited	version,	rather	than	the	most
recent	version,	please	contact	the	GtoPdb	curators.
Database	links
SLC3	and	SLC7	families	of	heteromeric	amino	acid	transporters	(HATs)
https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=141
				SLC3	family
				https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=168
								Transporters
																rBAT
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=889
																4F2hc
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=890
				SLC7	family
				https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=169
								Transporters
																CAT1(High	affinity	cationic	amino	acid	transporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=891
																CAT2(Low	affinity	cationic	amino	acid	transporter	2)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=892
																CAT3(Cationic	amino	acid	transporter	3)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=893
																CAT4(Cationic	amino	acid	transporter	4)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=894
																Probable	cationic	amino	acid	transporter
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=895
																LAT1(L-type	amino	acid	transporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=896
																LAT2(L-type	amino	acid	transporter	2)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=897
																y+LAT1(y+L	amino	acid	transporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=898
																y+LAT2(y+L	amino	acid	transporter	2)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=899
																b0,+AT(b0,+-type	amino	acid	transporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=900
																Asc-1(Asc-type	amino	acid	transporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=901
																xCT(Cystine/glutamate	transporter)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=902
																AGT1
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=903
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